News Events
Pareto Healthcare Conference, Stockholm. Carl-Johan Dalsgaard will present at this Scandinavian investor event that brings together leading healthcare providers, biotech innovators, and investors for financial presentations and panels.
DNB Carnegie “Small & Mid Cap Seminar”, Stockholm. CEO Carl-Johan Dalsgaard presents at the event.
Young Star Masters Grevagården, Skövde. Part of the sales team is representing Intervacc at this prestigious show jumping competition for young horses, attended by a large number of breeders, horse owners, and riders.
Redeye “Investor Update: Intervacc – Strangvac progress”. Carl-Johan Dalsgaard will present at the event, which will be streamed digitally between 11:00 AM and 12:30 PM (Swedish time).
Havemeyer Meeting, Kansas, USA. Workshops on equine research. Andrew Waller and Romain Pailott speak at the Havemeyer Foundation Workshop “Addressing Strangles and Other Streptococcal Diseases.” Supported by Boehringer Ingelheim Animal Health, Equine Diagnostic Solutions, Intervacc, and Merck Animal Health.
THE AGENDA
Upcoming activities
Spreading knowledge about quark, infection control and preventive animal health is an important part of Intervacc’s work. By participating in fairs, conferences and lectures, we want to contribute to increased knowledge and better animal health.
Being presented are planned activities where Intervacc participates in fairs, conferences, lectures among others.
Pareto Healthcare Conference, Stockholm. Carl-Johan Dalsgaard will present at this Scandinavian investor event that brings together leading healthcare providers, biotech innovators, and investors for financial presentations and panels.
DNB Carnegie “Small & Mid Cap Seminar”, Stockholm. CEO Carl-Johan Dalsgaard presents at the event.
Young Star Masters Grevagården, Skövde. Part of the sales team is representing Intervacc at this prestigious show jumping competition for young horses, attended by a large number of breeders, horse owners, and riders.
Redeye “Investor Update: Intervacc – Strangvac progress”. Carl-Johan Dalsgaard will present at the event, which will be streamed digitally between 11:00 AM and 12:30 PM (Swedish time).
Havemeyer Meeting, Kansas, USA. Workshops on equine research. Andrew Waller and Romain Pailott speak at the Havemeyer Foundation Workshop “Addressing Strangles and Other Streptococcal Diseases.” Supported by Boehringer Ingelheim Animal Health, Equine Diagnostic Solutions, Intervacc, and Merck Animal Health.
THE AGENDA
Upcoming activities
Raising awareness of strangles, infection control and preventive animal health is an important part of Intervacc’s work. By participating in trade fairs, meetings, training courses, conferences and lectures, we aim to contribute to greater knowledge and improved animal health.
Here we present major scheduled activities in which Intervacc participates.
With the news briefs, we want to offer an insight into the business between the regulatory news and the quarterly reports – which reflect the people, research, collaborations and activities behind the development of new vaccines and sales.
NEWS BRIEFS
Astrid and Anna-Carin Increase Their Holdings
Insider purchases between July 9-17, 2026, have been reported to FI for Chief Marketing and Sales Officer Anna-Carin Lagerlöf (120,000 shares) and Program Manager Astrid Larberg (115,484 shares).
The acquisition is linked to the company’s incentive program, LTI 2026.
The Product Portfolio Expands Further
In addition to our proprietary vaccine Strangvac®, Intervacc’s product portfolio includes a wide range of veterinary medicinal products and vaccines from the European pharmaceutical manufacturers Syva and Divasa-Farmavic in Spain, Animalcare in the United Kingdom, and Chemvet in Denmark.
Today, the range was expanded with an equine ointment from Derma Advanced.
Lars Stubberud – a welcome addition
Intervacc has appointed a new employee, Lars Stubberud, who joins the management team as Chief Technical Officer. Lars most recently comes from Calliditas Therapeutics AB, where he served as Head of Technical Operations. Lars has more than 30 years of experience in the pharmaceutical industry within the broader field of CMC, which includes product development, technology transfer/technical management, as well as regulatory affairs and quality assurance.
We would like to extend a very warm welcome to Lars at Intervacc!
Three Members of Management Team Increase Their Holdings
The new incentive program, LTI 2026, is a long-term performance-based share savings program that the Annual General Meeting decided to implement on May 13, 2026.
Insider purchases have been reported to the Swedish Financial Supervisory Authority between June 11-30 for Chief Marketing and Sales Officer Anna-Carin Lagerlöf (50,000 shares), Chief Financial Officer Jan Persson (250,000 shares), and Program Director Astrid Larberg (55,751 shares).
Intervacc’s CEO Carl-Johan Dalsgaard Increases His Holding
Insider purchases totaling 400,000 shares for a total sum of SEK 518,315 were reported to the Swedish Financial Supervisory Authority on June 10 and June 11. The acquisition is linked to the company’s incentive program, LTI 2026.
Studies Published on Zooepidemicus
Intervacc’s Head of Research, Andrew Waller, and Head of Immunology, Romain Paillot, are co-authors of a new peer-reviewed and published article “Cross-protective effect of a multicomponent fusion protein vaccine during a natural episode of Streptococcus zooepidemicus respiratory disease in ponies“.
With our news items, we aim to offer insight into our operations between regulatory news and quarterly reports, reflecting the people, the research, the collaborations and the day-to-day work behind the development of new vaccines and sales.
Astrid and Anna-Carin Increase Their Holdings
Insider purchases between July 9-17, 2026, have been reported to FI for Chief Marketing and Sales Officer Anna-Carin Lagerlöf (120,000 shares) and Program Manager Astrid Larberg (115,484 shares).
The acquisition is linked to the company’s incentive program, LTI 2026.
The Product Portfolio Expands Further
In addition to our proprietary vaccine Strangvac®, Intervacc’s product portfolio includes a wide range of veterinary medicinal products and vaccines from the European pharmaceutical manufacturers Syva and Divasa-Farmavic in Spain, Animalcare in the United Kingdom, and Chemvet in Denmark.
Today, the range was expanded with an equine ointment from Derma Advanced.
Lars Stubberud – a welcome addition
Intervacc has appointed a new employee, Lars Stubberud, who joins the management team as Chief Technical Officer. Lars most recently comes from Calliditas Therapeutics AB, where he served as Head of Technical Operations. Lars has more than 30 years of experience in the pharmaceutical industry within the broader field of CMC, which includes product development, technology transfer/technical management, as well as regulatory affairs and quality assurance.
We would like to extend a very warm welcome to Lars at Intervacc!
Three Members of Management Team Increase Their Holdings
The new incentive program, LTI 2026, is a long-term performance-based share savings program that the Annual General Meeting decided to implement on May 13, 2026.
Insider purchases have been reported to the Swedish Financial Supervisory Authority between June 11-30 for Chief Marketing and Sales Officer Anna-Carin Lagerlöf (50,000 shares), Chief Financial Officer Jan Persson (250,000 shares), and Program Director Astrid Larberg (55,751 shares).
Intervacc’s CEO Carl-Johan Dalsgaard Increases His Holding
Insider purchases totaling 400,000 shares for a total sum of SEK 518,315 were reported to the Swedish Financial Supervisory Authority on June 10 and June 11. The acquisition is linked to the company’s incentive program, LTI 2026.
Studies Published on Zooepidemicus
Intervacc’s Head of Research, Andrew Waller, and Head of Immunology, Romain Paillot, are co-authors of a new peer-reviewed and published article “Cross-protective effect of a multicomponent fusion protein vaccine during a natural episode of Streptococcus zooepidemicus respiratory disease in ponies“.
NEWS ITEMS
Astrid and Anna-Carin Increase Their Holdings
Insider purchases between July 9-17, 2026, have been reported to FI for Chief Marketing and Sales Officer Anna-Carin Lagerlöf (120,000 shares) and Program Manager Astrid Larberg (115,484 shares).
The acquisition is linked to the company’s incentive program, LTI 2026.
The Product Portfolio Expands Further
In addition to our proprietary vaccine Strangvac®, Intervacc’s product portfolio includes a wide range of veterinary medicinal products and vaccines from the European pharmaceutical manufacturers Syva and Divasa-Farmavic in Spain, Animalcare in the United Kingdom, and Chemvet in Denmark.
Today, the range was expanded with an equine ointment from Derma Advanced.
Lars Stubberud – a welcome addition
Intervacc has appointed a new employee, Lars Stubberud, who joins the management team as Chief Technical Officer. Lars most recently comes from Calliditas Therapeutics AB, where he served as Head of Technical Operations. Lars has more than 30 years of experience in the pharmaceutical industry within the broader field of CMC, which includes product development, technology transfer/technical management, as well as regulatory affairs and quality assurance.
We would like to extend a very warm welcome to Lars at Intervacc!
Three Members of Management Team Increase Their Holdings
The new incentive program, LTI 2026, is a long-term performance-based share savings program that the Annual General Meeting decided to implement on May 13, 2026.
Insider purchases have been reported to the Swedish Financial Supervisory Authority between June 11-30 for Chief Marketing and Sales Officer Anna-Carin Lagerlöf (50,000 shares), Chief Financial Officer Jan Persson (250,000 shares), and Program Director Astrid Larberg (55,751 shares).
Intervacc’s CEO Carl-Johan Dalsgaard Increases His Holding
Insider purchases totaling 400,000 shares for a total sum of SEK 518,315 were reported to the Swedish Financial Supervisory Authority on June 10 and June 11. The acquisition is linked to the company’s incentive program, LTI 2026.
Studies Published on Zooepidemicus
Intervacc’s Head of Research, Andrew Waller, and Head of Immunology, Romain Paillot, are co-authors of a new peer-reviewed and published article “Cross-protective effect of a multicomponent fusion protein vaccine during a natural episode of Streptococcus zooepidemicus respiratory disease in ponies“.